



X GP/1642 #9 NW
ATTORNEY DOCKET NO. 14114.0332U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

Chang :

Group Art Unit: 1642

Confirmation No. 5492 :

Examiner: Unassigned

Serial No. 09/701,536 :

Filed: November 29, 2000 :

For: "NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION" :

RECEIVED

MAR 05 2002

TECH CENTER 1600/2900

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT SUBMITTED
IN ACCORDANCE WITH THE PROVISIONS OF 37 C.F.R. §1.97(b)**

Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

February 15, 2002

Sir:


Submitted herewith on Form PTO 1449 is a listing of documents known to applicants and/or their attorneys pursuant to the requirements of 37 C.F.R. §1.56. A copy of each of these documents is enclosed.

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.

As these documents are considered to be timely filed, no fee is believed due. However, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.



Mary Miller
Registration No. 39,303

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date listed below



Mary Miller

February 15, 2002

Date



RECEIVED

ATTORNEY DOCKET NO. 14114.0332U2

SERIAL NO. 09/701.536

Page 1 of 2

MAR 05 2002

TECH CENTER 1600/2900

Form PTO-1449
U.S. DEPARTMENT OF COMMERCE (Rev. 7-80)
PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.: 14114.0332U2

SERIAL NO. 09/701,536

APPLICANT: Chang

LIST OF PRIOR ART CITED BY APPLICANT
(Use several sheets if necessary)

FILING DATE: June 18, 2001

GROUP: Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Alvarez et al. A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients. <i>Hum. Gene Ther.</i> 8:229-242 (January 20, 1997)
C2	Selay. The Choice Carrier. <i>Synthetic Vaccines Volume I</i> (edited by Arnon) CRC Press Inc., Boca Raton, FL. pp. 83-92 (1987)
C3	Clarke et al. Techniques For Hemagglutination And Hemagglutination-Inhibition With Arthropod-Borne Viruses. <i>Amer. J. Trop. Med. and Hyg.</i> 7:561-573 (1958)
C4	Gruenberg et al. Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains. <i>J. Gen. Virol.</i> 69:1391-1398 (1988)
C5	Heinz et al. Flaviviruses. In <i>Immunochemistry of Viruses II: The Basis for Serodiagnosis and Vaccines</i> . (edited by von Regenmortel and Neurath) Elsevier Science Publishers. Chapter 14, pp. 89-305 (1990)
C6	Henchal et al. Dengue Virus-Specific And Flavivirus Group Determinants Identified With Monoclonal Antibodies By Indirect Immunofluorescence. <i>Amer. J. Trop. Med. Hyg.</i> 31:830-836 (1982)
C7	Hubálek et al. West Nile Fever-a Reemerging Mosquito-Borne Viral Disease in Europe. <i>Emerg. Infect. Dis.</i> 5(5):643-650 (1999)
C8	Kohler et al. Continuous cultures of fused cells secreting antibody of predefined specificity. <i>Nature</i> 256:495-497 (August 7, 1975)
C9	Konishi et al. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. <i>Vaccine</i> 12(7):633-638 (1994)
C10	Kozak. Circumstances and Mechanisms of Inhibition of Translation by Secondary Structure in Eucaryotic mRNAs. <i>Mol. Cell. Biol.</i> 9(11):5134-5142 (November 1989)
C11	Laemmli. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. <i>Nature</i> 227:680-685 (August 15, 1970)
C12	Lai et al. Immunization of Monkeys with Baculovirus Recombinant-expressed Dengue Envelope and NS1 Glycoproteins Induces Partial Resistance to Challenge with Homotypic Dengue Virus. In <i>Vaccines 90: Modern Approaches to New Vaccines including Prevention of AIDS</i> , Cold Spring Harbor Laboratory, Cold Springs Harbor, NY pp. 119-124 (1990)

MAR 05 2002

TECH CENTER 1600/2900

	C13	Mason et al. Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1. <i>Virology</i> 161:262-267 (1987)
	C14	Smithburn et al. A Neurotropic Virus Isolated From The Blood Of A Native Of Uganda. <i>Am. J. Trop. Med. Hyg.</i> 20:471-492 (1940)
	C15	Tardei et al. Evaluation of Immunoglobulin M (IgM) and IgG Enzyme Immunoassays in Serologic Diagnosis of West Nile Virus Infection. <i>J. Clin. Microbiol.</i> 38(6):2232-2239 (June 2000)
	C16	Tsai et al. Japanese Encephalitis Vaccines. In <i>Vaccines</i> (3 rd edition) (edited by Plotkin and Orenstein), W.B. Saunders Co., Philadelphia, PA. Chapter 27, pp. 672-710 (1999)
	C17	Tsai et al. Japanese Encephalitis Vaccines. In <i>Vaccines</i> (2nd edition) (edited by Plotkin and Mortimer), W.B. Saunders Co., Philadelphia, PA. Chapter 24, pp. 671-713 (1994)
	C18	Yang et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. <i>Nature</i> 382:319-324 (July 25, 1996)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.